Structured Review

Novoprotein he4
Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, <t>HE4,</t> and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.
He4, supplied by Novoprotein, used in various techniques. Bioz Stars score: 88/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/he4/product/Novoprotein
Average 88 stars, based on 3 article reviews
Price from $9.99 to $1999.99
he4 - by Bioz Stars, 2022-09
88/100 stars

Images

1) Product Images from "Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes"

Article Title: Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes

Journal: Journal of Ovarian Research

doi: 10.1186/s13048-014-0109-z

Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, HE4, and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.
Figure Legend Snippet: Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, HE4, and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.

Techniques Used: Over Expression, Polymerase Chain Reaction, Expressing, Amplification, Staining, Quantitative RT-PCR

CA-125 and HE4 levels were both increased in only 58% of serum samples of early stage serous carcinoma patients as measured by ELISA. CA-125 (A) and HE4 (B) production was measured by ELISA. Levels of these proteins were calculated as averages of triplicates. The line across the figures is the low threshold for protein up-regulation. An asterisk (*) indicates that this particular patient demonstrated no up-regulation in both CA-125 and HE4.
Figure Legend Snippet: CA-125 and HE4 levels were both increased in only 58% of serum samples of early stage serous carcinoma patients as measured by ELISA. CA-125 (A) and HE4 (B) production was measured by ELISA. Levels of these proteins were calculated as averages of triplicates. The line across the figures is the low threshold for protein up-regulation. An asterisk (*) indicates that this particular patient demonstrated no up-regulation in both CA-125 and HE4.

Techniques Used: Enzyme-linked Immunosorbent Assay

2) Product Images from "HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria"

Article Title: HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria

Journal: Protein and peptide letters

doi:

Several Proteins are Upregulated by End1 Epithelia in Response to A. vaginae stimulation The following volumes of CM were concentrated, resolved, and immunoblotted for protein detection: 300 µl for Lipocalin 2; 400 µl for Cyclophilin A; 450 µl for Trappin-2 and 2000 µl for HE4. Recombinant standards (labeled as ng/lane) were resolved alongside CM to estimate protein content. One representative of three independent experiments for each analyte is shown.
Figure Legend Snippet: Several Proteins are Upregulated by End1 Epithelia in Response to A. vaginae stimulation The following volumes of CM were concentrated, resolved, and immunoblotted for protein detection: 300 µl for Lipocalin 2; 400 µl for Cyclophilin A; 450 µl for Trappin-2 and 2000 µl for HE4. Recombinant standards (labeled as ng/lane) were resolved alongside CM to estimate protein content. One representative of three independent experiments for each analyte is shown.

Techniques Used: Recombinant, Labeling

Recombinant Proteins Enhance HIV Infection in the Presence of A. vaginae -Inoculated End1 CM Recombinant proteins lipocalin 2, cyclophilin A, trappin-2 or HE4 were added to the TZM-bl reporter assay at 0.1–100 ng/ml, in the presence of A) mock-inoculated End1 CM, or B) A. vaginae -inoculated End1 CM. CM was added at 4X concentration in all conditions. Asterisks (*=p
Figure Legend Snippet: Recombinant Proteins Enhance HIV Infection in the Presence of A. vaginae -Inoculated End1 CM Recombinant proteins lipocalin 2, cyclophilin A, trappin-2 or HE4 were added to the TZM-bl reporter assay at 0.1–100 ng/ml, in the presence of A) mock-inoculated End1 CM, or B) A. vaginae -inoculated End1 CM. CM was added at 4X concentration in all conditions. Asterisks (*=p

Techniques Used: Recombinant, Infection, Reporter Assay, Concentration Assay

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Novoprotein he4 exogenous active protein
    Interaction of <t>HE4,</t> ANXA2 and P-gp in CAOV3 cells. (A) Protein lysates of CAOV3 cells were precipitated using HE4, ANXA2 and P-gp-specific antibodies. WB revealed co-expression of HE4 with ANXA2, and ANXA2 with P-gp, respectively. (B) Double-labeling immunofluorescence showed the colocalization of HE4 or ANXA2 with P-gp in CAOV3 cells. Magnification, ×400. HE4; human epididymis protein 4; P-gp, P-glycoprotein; WB, western blotting; TCL, total cell lysate; NTC, negative control, the primary antibody was replaced by rabbit IgG; IP, immunoprecipitate.
    He4 Exogenous Active Protein, supplied by Novoprotein, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/he4 exogenous active protein/product/Novoprotein
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    he4 exogenous active protein - by Bioz Stars, 2022-09
    90/100 stars
      Buy from Supplier

    88
    Novoprotein he4
    Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, <t>HE4,</t> and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.
    He4, supplied by Novoprotein, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/he4/product/Novoprotein
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    he4 - by Bioz Stars, 2022-09
    88/100 stars
      Buy from Supplier

    Image Search Results


    Interaction of HE4, ANXA2 and P-gp in CAOV3 cells. (A) Protein lysates of CAOV3 cells were precipitated using HE4, ANXA2 and P-gp-specific antibodies. WB revealed co-expression of HE4 with ANXA2, and ANXA2 with P-gp, respectively. (B) Double-labeling immunofluorescence showed the colocalization of HE4 or ANXA2 with P-gp in CAOV3 cells. Magnification, ×400. HE4; human epididymis protein 4; P-gp, P-glycoprotein; WB, western blotting; TCL, total cell lysate; NTC, negative control, the primary antibody was replaced by rabbit IgG; IP, immunoprecipitate.

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: Interaction of HE4, ANXA2 and P-gp in CAOV3 cells. (A) Protein lysates of CAOV3 cells were precipitated using HE4, ANXA2 and P-gp-specific antibodies. WB revealed co-expression of HE4 with ANXA2, and ANXA2 with P-gp, respectively. (B) Double-labeling immunofluorescence showed the colocalization of HE4 or ANXA2 with P-gp in CAOV3 cells. Magnification, ×400. HE4; human epididymis protein 4; P-gp, P-glycoprotein; WB, western blotting; TCL, total cell lysate; NTC, negative control, the primary antibody was replaced by rabbit IgG; IP, immunoprecipitate.

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Western Blot, Expressing, Labeling, Immunofluorescence, Negative Control

    The association between HE4 expression, P-gp expression, drug resistance or FIGO stage and survival time of patients with ovarian cancer. Kaplan-Meier survival analysis showed that a (A) high expression of HE4, (B) high expressions of P-gp, (C) drug resistance, (D) late FIGO stage were independent risk factors for overall survival. HE4; human epididymis protein 4; P-gp, P-glycoprotein; FIGO, Federation of Gynecology and Obstetrics; Cum survival, cumulative survival.

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: The association between HE4 expression, P-gp expression, drug resistance or FIGO stage and survival time of patients with ovarian cancer. Kaplan-Meier survival analysis showed that a (A) high expression of HE4, (B) high expressions of P-gp, (C) drug resistance, (D) late FIGO stage were independent risk factors for overall survival. HE4; human epididymis protein 4; P-gp, P-glycoprotein; FIGO, Federation of Gynecology and Obstetrics; Cum survival, cumulative survival.

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Expressing

    Inhibitory regulation of hsa-miR-129-5p by HE4 via interactions with ANXA2. (A) Expression of five miRNAs expression before and after transfection, detected by reverse transcription-quantitative polymerase chain reaction assays. (B) Expression of hsa-miR-129-5p in cells before and after treatment by different antibodies or active protein at different time points. The cells of each group were treated as same as described for Fig. 3H . *P

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: Inhibitory regulation of hsa-miR-129-5p by HE4 via interactions with ANXA2. (A) Expression of five miRNAs expression before and after transfection, detected by reverse transcription-quantitative polymerase chain reaction assays. (B) Expression of hsa-miR-129-5p in cells before and after treatment by different antibodies or active protein at different time points. The cells of each group were treated as same as described for Fig. 3H . *P

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Expressing, Transfection, Real-time Polymerase Chain Reaction

    Interaction of HE4 with ANXA2 enhances P-gp expression and promotes resistance to adriamycin in CAOV3 cells. (A) Expression of HE4, ANXA2 and P-gp before and after transfection, detected by western blotting. (B) Comparison of HE4, ANXA2 and P-gp protein levels before and after transfection. (C) Expression of HE4, ANXA2 and P-gp before and after transfection, detected by RT-qPCR assays. (D) Cells were treated with 0–10 µg/ml adriamycin for 24 h before and after transfection, at which time the cells were subjected to MTT assay to measure viability. Results are displayed as percent survival of vehicle-treated cells. Error bars represent the standard deviation of biological replicates. (E) Flow cytometry detection of the expression of P-gp on the cell membrane before and after transfection. (F) Measurement of adriamycin accumulation by flow cytometry before and after transfection, cells of different groups were pretreated with complete medium containing or not containing verapamil (50 µM) for 1 h. After pretreatment, cells were incubated with adriamycin in culture medium. (G) Measurement of MFI of adriamycin by flow cytometry in cells before and after transfection. (H) Expression of P-gp in cells before and after treatment by different antibodies or active protein at different time points, detected by western blotting. Group 1, CAOV3 cells; group 2, CAOV3 cells treated with HE4 active protein; group 3, CAOV3 cells treated with ANXA2 active protein; group 4, CAOV3 cells treated with HE4 antibody; group 5, CAOV3 cells treated with ANXA2 antibody; group 6, CAOV3 cells treated with HE4 active protein and ANXA2 antibody; group 7, CAOV3-A2-L cells; group 8, CAOV3-A2-L cells treated with HE4 active protein; and group 9, CAOV3 cells treated with IgG. (I) Comparison of P-gp protein levels before and after treatment by different antibodies or active protein at different time points. The cells of each group were treated as same as (H). (J) Expression of P-gp in cells before and after treatment by different antibodies or active protein at different time points, detected by RT-qPCR assays. The cells of each group were treated as same as (H). *P

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: Interaction of HE4 with ANXA2 enhances P-gp expression and promotes resistance to adriamycin in CAOV3 cells. (A) Expression of HE4, ANXA2 and P-gp before and after transfection, detected by western blotting. (B) Comparison of HE4, ANXA2 and P-gp protein levels before and after transfection. (C) Expression of HE4, ANXA2 and P-gp before and after transfection, detected by RT-qPCR assays. (D) Cells were treated with 0–10 µg/ml adriamycin for 24 h before and after transfection, at which time the cells were subjected to MTT assay to measure viability. Results are displayed as percent survival of vehicle-treated cells. Error bars represent the standard deviation of biological replicates. (E) Flow cytometry detection of the expression of P-gp on the cell membrane before and after transfection. (F) Measurement of adriamycin accumulation by flow cytometry before and after transfection, cells of different groups were pretreated with complete medium containing or not containing verapamil (50 µM) for 1 h. After pretreatment, cells were incubated with adriamycin in culture medium. (G) Measurement of MFI of adriamycin by flow cytometry in cells before and after transfection. (H) Expression of P-gp in cells before and after treatment by different antibodies or active protein at different time points, detected by western blotting. Group 1, CAOV3 cells; group 2, CAOV3 cells treated with HE4 active protein; group 3, CAOV3 cells treated with ANXA2 active protein; group 4, CAOV3 cells treated with HE4 antibody; group 5, CAOV3 cells treated with ANXA2 antibody; group 6, CAOV3 cells treated with HE4 active protein and ANXA2 antibody; group 7, CAOV3-A2-L cells; group 8, CAOV3-A2-L cells treated with HE4 active protein; and group 9, CAOV3 cells treated with IgG. (I) Comparison of P-gp protein levels before and after treatment by different antibodies or active protein at different time points. The cells of each group were treated as same as (H). (J) Expression of P-gp in cells before and after treatment by different antibodies or active protein at different time points, detected by RT-qPCR assays. The cells of each group were treated as same as (H). *P

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Expressing, Transfection, Western Blot, Quantitative RT-PCR, MTT Assay, Standard Deviation, Flow Cytometry, Incubation

    Expression of HE4 and P-gp in ovarian cancer tissue. IHC to detect the expression of HE4 in (A) the resistant group and (B) the sensitive group. IHC to detect the expression of P-gp in (C) the resistant group and (D) in the sensitive group. Magnification, ×400. HE4; human epididymis protein 4; P-gp, P-glycoprotein; IHC, immunohistochemistry.

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: Expression of HE4 and P-gp in ovarian cancer tissue. IHC to detect the expression of HE4 in (A) the resistant group and (B) the sensitive group. IHC to detect the expression of P-gp in (C) the resistant group and (D) in the sensitive group. Magnification, ×400. HE4; human epididymis protein 4; P-gp, P-glycoprotein; IHC, immunohistochemistry.

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Expressing, Immunohistochemistry

    Expression of HE4, ANXA2 and P-gp in ovarian cancer cells (CAOV3, SKOV3 and OVCAR3). (A) Western blot analysis of HE4, ANXA2 and P-gp expression in three cell lines. (B) Comparison of HE4, ANXA2 and P-gp protein levels in three cell lines. (C) Immunocytochemistry detection of P-gp expression in three cell lines. Magnification, ×400. *P

    Journal: Molecular Medicine Reports

    Article Title: Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II

    doi: 10.3892/mmr.2021.12135

    Figure Lengend Snippet: Expression of HE4, ANXA2 and P-gp in ovarian cancer cells (CAOV3, SKOV3 and OVCAR3). (A) Western blot analysis of HE4, ANXA2 and P-gp expression in three cell lines. (B) Comparison of HE4, ANXA2 and P-gp protein levels in three cell lines. (C) Immunocytochemistry detection of P-gp expression in three cell lines. Magnification, ×400. *P

    Article Snippet: IgG (BIOSS; cat. no. bs-0295P), HE4 exogenous active protein (100 ng/ml; Novoprotein; cat. no. C550A), ANXA2 exogenous active protein (10 ng/ml; Novoprotein; cat. no. C205A), HE4 antibodies (10 µg/ml; Abcam; cat. no. ab109298), ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig), or ANXA2 antibodies (10 µg/ml; ProteinTech Group, Inc.; cat. no. 66035-1-Ig) with HE4 exogenous active protein, was added to the adherent cells.

    Techniques: Expressing, Western Blot, Immunocytochemistry

    Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, HE4, and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.

    Journal: Journal of Ovarian Research

    Article Title: Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes

    doi: 10.1186/s13048-014-0109-z

    Figure Lengend Snippet: Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages, stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, HE4, and CEA) relative to normal ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.

    Article Snippet: Recombinant human CA-125 (R & D Systems, Minneapolis, MN) or HE4 (Novoprotein, Summit, NJ) were used as positive controls and further diluted as standards.

    Techniques: Over Expression, Polymerase Chain Reaction, Expressing, Amplification, Staining, Quantitative RT-PCR

    CA-125 and HE4 levels were both increased in only 58% of serum samples of early stage serous carcinoma patients as measured by ELISA. CA-125 (A) and HE4 (B) production was measured by ELISA. Levels of these proteins were calculated as averages of triplicates. The line across the figures is the low threshold for protein up-regulation. An asterisk (*) indicates that this particular patient demonstrated no up-regulation in both CA-125 and HE4.

    Journal: Journal of Ovarian Research

    Article Title: Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes

    doi: 10.1186/s13048-014-0109-z

    Figure Lengend Snippet: CA-125 and HE4 levels were both increased in only 58% of serum samples of early stage serous carcinoma patients as measured by ELISA. CA-125 (A) and HE4 (B) production was measured by ELISA. Levels of these proteins were calculated as averages of triplicates. The line across the figures is the low threshold for protein up-regulation. An asterisk (*) indicates that this particular patient demonstrated no up-regulation in both CA-125 and HE4.

    Article Snippet: Recombinant human CA-125 (R & D Systems, Minneapolis, MN) or HE4 (Novoprotein, Summit, NJ) were used as positive controls and further diluted as standards.

    Techniques: Enzyme-linked Immunosorbent Assay

    Several Proteins are Upregulated by End1 Epithelia in Response to A. vaginae stimulation The following volumes of CM were concentrated, resolved, and immunoblotted for protein detection: 300 µl for Lipocalin 2; 400 µl for Cyclophilin A; 450 µl for Trappin-2 and 2000 µl for HE4. Recombinant standards (labeled as ng/lane) were resolved alongside CM to estimate protein content. One representative of three independent experiments for each analyte is shown.

    Journal: Protein and peptide letters

    Article Title: HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria

    doi:

    Figure Lengend Snippet: Several Proteins are Upregulated by End1 Epithelia in Response to A. vaginae stimulation The following volumes of CM were concentrated, resolved, and immunoblotted for protein detection: 300 µl for Lipocalin 2; 400 µl for Cyclophilin A; 450 µl for Trappin-2 and 2000 µl for HE4. Recombinant standards (labeled as ng/lane) were resolved alongside CM to estimate protein content. One representative of three independent experiments for each analyte is shown.

    Article Snippet: For immunoblotting, the following recombinant proteins were used as standards: Lipocalin-2 (Abcam ab95007); Cyclophilin-A (Abcam ab86219); Trappin-2 (Novoprotein CA39); HE4 (Novoprotein C550).

    Techniques: Recombinant, Labeling

    Recombinant Proteins Enhance HIV Infection in the Presence of A. vaginae -Inoculated End1 CM Recombinant proteins lipocalin 2, cyclophilin A, trappin-2 or HE4 were added to the TZM-bl reporter assay at 0.1–100 ng/ml, in the presence of A) mock-inoculated End1 CM, or B) A. vaginae -inoculated End1 CM. CM was added at 4X concentration in all conditions. Asterisks (*=p

    Journal: Protein and peptide letters

    Article Title: HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria

    doi:

    Figure Lengend Snippet: Recombinant Proteins Enhance HIV Infection in the Presence of A. vaginae -Inoculated End1 CM Recombinant proteins lipocalin 2, cyclophilin A, trappin-2 or HE4 were added to the TZM-bl reporter assay at 0.1–100 ng/ml, in the presence of A) mock-inoculated End1 CM, or B) A. vaginae -inoculated End1 CM. CM was added at 4X concentration in all conditions. Asterisks (*=p

    Article Snippet: For immunoblotting, the following recombinant proteins were used as standards: Lipocalin-2 (Abcam ab95007); Cyclophilin-A (Abcam ab86219); Trappin-2 (Novoprotein CA39); HE4 (Novoprotein C550).

    Techniques: Recombinant, Infection, Reporter Assay, Concentration Assay